Comparative Pharmacology
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus NAQUA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROTHIAZIDE SODIUM versus NAQUA.
CHLOROTHIAZIDE SODIUM vs NAQUA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits sodium-chloride symporter in distal convoluted tubule of nephron, reducing sodium reabsorption and promoting diuresis.
Inhibition of sodium-chloride symporter (NCC) in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis.
500 mg to 1 g orally or intravenously once or twice daily.
Oral: 5-10 mg once daily, preferably in the morning. Maximum dose 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is 45–120 minutes in patients with normal renal function; prolonged in renal impairment (up to 24 hours in anuria).
Terminal elimination half-life is 6-12 hours; prolonged in renal impairment (up to 20-30 hours) or heart failure due to reduced renal perfusion.
Primarily renal excretion via tubular secretion; approximately 95% of absorbed dose excreted unchanged in urine within 24 hours, with less than 5% eliminated via bile/feces.
Primarily renal elimination; approximately 60-80% excreted unchanged in urine via tubular secretion; minor biliary/fecal excretion (<10%).
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic